WuXi Biologics (Cayman) Beheer

Beheer criteriumcontroles 2/4

De CEO WuXi Biologics (Cayman)'s is Chris Chen, benoemd in Jan2016, heeft een ambtstermijn van 8.75 jaar. De totale jaarlijkse vergoeding van { bedraagt CN¥ 96.91M, bestaande uit 4.1% salaris en 95.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.35% van de aandelen van het bedrijf, ter waarde HK$ 249.38M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.1 jaar en 7.1 jaar.

Belangrijke informatie

Chris Chen

Algemeen directeur

CN¥96.9m

Totale compensatie

Percentage CEO-salaris	4.1%
Dienstverband CEO	8.8yrs
Eigendom CEO	0.3%
Management gemiddelde ambtstermijn	2.1yrs
Gemiddelde ambtstermijn bestuur	7.1yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Chris Chen's beloning veranderd ten opzichte van WuXi Biologics (Cayman)'s winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	CN¥3b
Mar 31 2024	n/a	n/a	CN¥3b
Dec 31 2023	CN¥97m	CN¥4m	CN¥3b
Sep 30 2023	n/a	n/a	CN¥4b
Jun 30 2023	n/a	n/a	CN¥4b
Mar 31 2023	n/a	n/a	CN¥4b
Dec 31 2022	CN¥79m	CN¥3m	CN¥4b
Sep 30 2022	n/a	n/a	CN¥4b
Jun 30 2022	n/a	n/a	CN¥4b
Mar 31 2022	n/a	n/a	CN¥4b
Dec 31 2021	CN¥51m	CN¥3m	CN¥3b
Sep 30 2021	n/a	n/a	CN¥3b
Jun 30 2021	n/a	n/a	CN¥3b
Mar 31 2021	n/a	n/a	CN¥2b
Dec 31 2020	CN¥31m	CN¥3m	CN¥2b
Sep 30 2020	n/a	n/a	CN¥1b
Jun 30 2020	n/a	n/a	CN¥1b
Mar 31 2020	n/a	n/a	CN¥1b
Dec 31 2019	CN¥25m	CN¥3m	CN¥1b
Sep 30 2019	n/a	n/a	CN¥922m
Jun 30 2019	n/a	n/a	CN¥831m
Mar 31 2019	n/a	n/a	CN¥731m
Dec 31 2018	CN¥20m	CN¥2m	CN¥631m
Sep 30 2018	n/a	n/a	CN¥520m
Jun 30 2018	n/a	n/a	CN¥410m
Mar 31 2018	n/a	n/a	CN¥331m
Dec 31 2017	CN¥24m	CN¥2m	CN¥253m

Compensatie versus markt: De totale vergoeding ($USD 13.81M ) Chris } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Hong Kong markt ($USD 737.10K ).

Compensatie versus inkomsten: De beloning van Chris is het afgelopen jaar met meer dan 20% gestegen, terwijl de winst van het bedrijf met meer dan 20% is gedaald.

CEO

Chris Chen (51 yo)

8.8yrs

Tenure

CN¥96,911,000

Compensatie

Dr. Zhisheng Chen, also known as Chris, Ph.D. has been the Chief Executive Officer & Executive Director at WuXi Biologics (Cayman) Inc. since January 01, 2016 and since February 27, 2014 respectively. Dr....

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Ge Li	Founder & Chairman	10.7yrs	geen gegevens	geen gegevens
Zhisheng Chen	CEO & Executive Director	8.8yrs	CN¥96.91m	0.35% HK$ 248.5m
Weichang Zhou	Honorary President of Global Biologics Development	9.5yrs	CN¥32.89m	0.012% HK$ 8.4m
Ming Tu	CFO & Executive VP	2.9yrs	geen gegevens	geen gegevens
Lihua Yu	COO & Senior VP	less than a year	geen gegevens	geen gegevens
Sherry Gu	Chief Technology Officer and Executive VP of Global Biologics Development Department	less than a year	geen gegevens	geen gegevens
Jijie Gu	Chief Scientific Officer & President of Global Biologics Research	no data	geen gegevens	geen gegevens
Lina Fan	Senior VP & Head of Investor Relations	less than a year	geen gegevens	geen gegevens
Cong Ding	VP & Head of Legal Department	no data	geen gegevens	geen gegevens
He Wang	Chief Compliance Officer	2.1yrs	geen gegevens	geen gegevens
Li Xiong	VP & Head of Global Human Resources	no data	geen gegevens	geen gegevens
Angus Scott Turner	Senior VP and Head of Global BD & Alliance Management	no data	geen gegevens	geen gegevens

2.1yrs

Gemiddelde duur

56yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 2269 wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.1 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Ge Li	Founder & Chairman	10.7yrs	geen gegevens	geen gegevens
Zhisheng Chen	CEO & Executive Director	10.7yrs	CN¥96.91m	0.35% HK$ 248.5m
Weichang Zhou	Honorary President of Global Biologics Development	8.4yrs	CN¥32.89m	0.012% HK$ 8.4m
Jackson Tai	Independent Non-Executive Director	1.4yrs	CN¥710.00k	0.00063% HK$ 450.9k
James Larrick	Member of Scientific Advisory Board	6.8yrs	geen gegevens	geen gegevens
David D. Ho	Member of Scientific Advisory Board	6.8yrs	geen gegevens	geen gegevens
Wei-Shou Hu	Member of Scientific Advisory Board	6.8yrs	geen gegevens	geen gegevens
Ram Sasisekharan	Member of Scientific Advisory Board	6.8yrs	geen gegevens	geen gegevens
William Robert Keller	Independent Non-Executive Director	7.4yrs	CN¥906.00k	0.00053% HK$ 379.4k
Yanling Cao	Non-Executive Director	8.4yrs	geen gegevens	geen gegevens
Yibing Wu	Non-Executive Director	8.4yrs	geen gegevens	geen gegevens
Kenneth Walton Hitchner	Independent Non-Executive Director	4.3yrs	CN¥933.00k	0.0050% HK$ 3.5m

7.1yrs

Gemiddelde duur

59.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 2269 wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.1 jaar).

WuXi Biologics (Cayman) Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

CEO & Executive Director recently sold HK$6.6m worth of stock

Less than half of directors are independent

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 19, 2024

Independent Non-Executive Director recently bought HK$3.0m worth of stock

WuXi Biologics (Cayman) Inc. Announces Executive Changes, Effective March 31, 2024

Recent updates

WuXi Biologics (Cayman) Inc. (SEHK:2269) completed the acquisition of remaining 30% stake in WuXi Vaccines (Cayman) Inc. from Shanghai Hile Bio-Technology Co., Ltd. (SHSE:603718).

Investor sentiment deteriorates as stock falls 16%

WuXi Reportedly Explores Sale of Pharma Units as US Restrictions Loom

First half 2024 earnings released: EPS: CN¥0.36 (vs CN¥0.55 in 1H 2023)

Investor sentiment improves as stock rises 16%

WuXi Biologics Successfully Completes First Scale-Up of High-Productivity Bioprocessing Platform WuXiUI in 2,000L GMP Manufacturing

First half 2024 earnings released: EPS: CN¥0.36 (vs CN¥0.55 in 1H 2023)

WuXi Biologics (Cayman) Inc. to Report First Half, 2024 Results on Aug 21, 2024

CEO & Executive Director recently sold HK$6.6m worth of stock

Investor sentiment deteriorates as stock falls 16%

Full year 2023 earnings released: EPS: CN¥0.82 (vs CN¥1.06 in FY 2022)

Less than half of directors are independent

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 19, 2024

Full year 2023 earnings released: EPS: CN¥0.82 (vs CN¥1.06 in FY 2022)

WuXi Biologics (Cayman) Inc.(SEHK:2269) dropped from S&P International 700

Investor sentiment deteriorates as stock falls 17%

WuXi Biologics (Cayman) Inc. to Report Q4, 2023 Results on Mar 26, 2024

Investor sentiment deteriorates as stock falls 18%

WuXi Biologics Successfully Completes First 1,6000L Manufacturing Run in Ireland

Investor sentiment deteriorates as stock falls 19%

WuXi Biologics Launches WuXia ADCC PLUS™ for the Development and Manufacturing of Afucosylated Antibodies that Elicit Enhanced ADCC Effect

Independent Non-Executive Director recently bought HK$3.0m worth of stock

WuXi Biologics Receives U.S. Patent for Proprietary Bispecific Antibody Technology Platform WuXiBody™

WuXi Biologics (Cayman) Inc. Announces Executive Changes, Effective March 31, 2024

Investor sentiment improves as stock rises 16%

WuXi Biologics (Cayman) Inc. (SEHK:2269) commences an Equity Buyback Plan for 424,841,177 shares, representing 10% of its issued share capital, under the authorization approved on June 27, 2023.

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 28%

CEO & Executive Director recently sold HK$6.0m worth of stock

Wuxi Biologics Successfully Implements Fully Integrated Continuous Process with Breakthrough Productivity of 6 g/L/Day At Pilot Scale

Now 21% undervalued

Board Member recently sold HK$25m worth of stock

Now 21% undervalued

WuXi Biologics Launches New High-Productivity Bioprocessing Platform WuXiUI™ for Cost-Effective Commercial Manufacturing and Desirable Product Quality

Investor sentiment improves as stock rises 16%

First half 2023 earnings released: EPS: CN¥0.55 (vs CN¥0.61 in 1H 2022)

Wuxi Biologics (Cayman) Inc. Announces Executive Changes

WuXi Biologics (Cayman) Inc. to Report First Half, 2023 Results on Aug 23, 2023

CEO & Executive Director recently sold HK$4.6m worth of stock

Investor sentiment deteriorates as stock falls 20%

CEO & Executive Director recently sold HK$13m worth of stock

Now 21% undervalued after recent price drop

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 15, 2023

WuXi Biologics (Cayman) Inc. Announces Demise of Ning Zhao, Non-Executive Director, Member of Remuneration Committee and Member of Environmental, Social and Governance Committee

Now 20% undervalued after recent price drop

WuXi Biologics (Cayman) Inc. Announces Board and Board Committee Changes

Now 20% undervalued after recent price drop

Investor sentiment improves as stock rises 16%

Now 20% undervalued after recent price drop

Full year 2022 earnings released: EPS: CN¥1.06 (vs CN¥0.81 in FY 2021)

WuXi Biologics (Cayman) Inc. to Report Fiscal Year 2022 Results on Mar 22, 2023

Investor sentiment improved over the past week

Now 22% undervalued after recent price drop

WuXi Biologics (Cayman) Inc. Announces Demise of Teh-Ming Walter Kwauk, Independent Non-Executive Director, the Chairman of the Audit Committee of the Company and A Member of the Nomination Committee of the Company

CEO & Executive Director recently sold HK$6.0m worth of stock

Wuxi Biologics (Cayman) Inc. Announces Appointments to Strategy Committee

Less than half of directors are independent

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

WuXi Biologics (Cayman) Inc. (SEHK:2269) commences an Equity Buyback Plan for 425,926,547 shares, representing 10% of its issued share capital, under the authorization approved on June 10, 2022.

WuXi Biologics (Cayman) Inc. Receives Regulatory Approvals for Drug Substance and Drug Product Facilities from U.S. FDA and EMA

Investor sentiment deteriorated over the past week

First half 2022 earnings released: EPS: CN¥0.61 (vs CN¥0.44 in 1H 2021)

WuXi Biologics (Cayman) Inc. Appoints Weichang Zhou as Member of the Strategy Committee

Now 21% undervalued

WuXi Biologics (Cayman) Inc. Provides Earnings Guidance for the Six Months Ended June 30, 2022

CEO & Executive Director recently sold HK$17m worth of stock

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Full year 2021 earnings released: EPS: CN¥0.81 (vs CN¥0.43 in FY 2020)